Month: March 2026

NASHVILLE, Tenn., March 11, 2026 (GLOBE NEWSWIRE) — Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”), a leading lodging and hospitality real estate investment trust that specializes in group-oriented, upscale convention center resorts and country music entertainment experiences, announced today that it will release its first quarter 2026 earnings results after the market closes on Thursday, April 30, 2026. Management will hold a conference call to discuss the quarter’s results at 10 a.m. ET on Friday, May 1, 2026. To participate in the conference call, please dial 800-225-9448 and use conference ID: RHPQ126. The call will be available for replay through May 8, 2026, by dialing 800-723-0607; a conference ID is not required. This call is also being webcast and can be accessed at the Company’s Investor Relations website...

LONDON, March 11, 2026 (GLOBE NEWSWIRE) — Fourth Quarter Financial HighlightsOn March 11, 2026, pursuant to the Company’s Capital Return Policy, the Board of Directors of Navigator Holdings Limited., (NYSE: NVGS) (“Navigator Holdings”, “Navigator Gas”, “our”, “we”, “us” or the “Company”) declared a cash dividend of $0.07 per share of the Company’s common stock for the quarter ended December 31, 2025, payable on March 31, 2026, to all shareholders of record as of the close of business U.S. Eastern Time on March 23, 2026 (the “Dividend”). Also as part of the Company’s Capital Return Policy for the quarter ended December 31, 2025, the Company expects to repurchase approximately $1.0 million of its common stock between March 13, 2026, and March 31, 2026, subject to operating needs, market conditions, legal requirements,...

Record annual revenue of $365.0 million in the fiscal year ending January 31, 2026,including a quarterly record of $96.1 million in the fiscal fourth quarter ending January 31, 2026Total Platform Assets up 17% year-over-year to a record $94.1 billion PALO ALTO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Wealthfront Corporation (Nasdaq: WLTH), a tech-driven financial platform helping digital natives turn their savings into wealth, announced financial results for its fiscal fourth quarter and full year ended January 31, 2026. David Fortunato – CEO, President & Director: “We capped off a milestone year in the fourth quarter as we went public and drove another quarter-end record in Total Platform Assets due in large part to a second consecutive record quarter in net cross account transfers from Cash Management to Investment...

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL) Completed a $50 million registered direct financing in January 2026 Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of the January 2026 financing, the company has cash runway into the first half of 2028 WATERTOWN, Mass., March 11, 2026 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company...

CALGARY, Alberta, March 11, 2026 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce that it has filed its audited annual financial statements (the “financial statements”) and related management’s discussion and analysis and its annual information form (the “AIF”) for the financial year ended December 31, 2025 (collectively, the “Annual Filings”). The AIF contains the reserves data and other oil and gas information as required by National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities. The financial and reserves information contained in the Annual Filings is consistent with the unaudited financial and reserves information disclosed in the press release issued by Birchcliff on February 11, 2026. The Annual Filings are available electronically on the...

Delivers financial performance above guidance ranges Full year 2025 worldwide net sales totaled $1 billion Full year gross margin expands 390 basis points to 56.1% Full year operating loss of $19 million and operating margin of (1.9)%; adjusted operating income of $12 million and adjusted operating margin of 1.1% Unveils next evolution of turnaround plan and raises long-term financial targetsRICHARDSON, Texas, March 11, 2026 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fourth quarter and fiscal year ended January 3, 2026. “The bold initiatives under the Turnaround Plan we announced one year ago gained traction quickly, enabling us to deliver operating and financial performance above our expectations for 2025,” said Franco Fogliato, CEO. “We focused on our core brands, channels...

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its second quarter and first six- months of fiscal year 2026.  Second Quarter Year to Date(in thousands, except per share amounts) Ended January 31, Ended January 31,  2026 2025 Change 2026 2025 ChangeConsolidated Results            Net Sales $ 117,737 $ 116,914 1 % $ 238,223 $ 244,859 (3)%Income from Operations * $ 15,693 $ 17,482 (10)% $ 32,647 $ 38,672 (16)%Net Income $ 12,569 $ 12,921 (3)% $ 28,025 $ 29,297 (4)%EBITDA † $ 21,735 $ 22,216 (2)% $ 45,376 $ 48,383 (6)%Diluted EPS – Common $ 0.87 $ 0.89 (2)% $ 1.93 $ 2.01 (4)%Business to Business            Net Sales $ 41,977 $ 43,416 (3)% $ 86,263 $ 91,831 (6)%Segment Operating...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. “We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated development plan for PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “In addition to oncology and...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the...